Home>>Defensin HNP-2 (human) (trifluoroacetate salt)

Defensin HNP-2 (human) (trifluoroacetate salt) (Synonyms: DEFA2 Protein, α-Defensin 2, Human Neutrophil Peptide 2, Neutrophil Defensin 2)

Catalog No.GC43397

Defensin HNP-2 is a peptide with antimicrobial properties that is secreted by human polymorphonuclear leukocytes (PMNs).

Products are for research use only. Not for human use. We do not sell to patients.

Defensin HNP-2 (human) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
100μg
$427.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Defensin HNP-2 is a peptide with antimicrobial properties that is secreted by human polymorphonuclear leukocytes (PMNs). It induces 26.2 and 43.5% lysis of mammalian cells at concentrations of 25 and 100 μg/ml, respectively. It also completely inhibits secretion of the exotoxin superantigen TSS toxin-1 (TSST-1) from S. aureus at a concentration of 5 ng/ml and inhibits infection of McCoy cells by C. trachomatis elementary bodies (EBs). Defensin HNP-2 binds to recombinant HIV-1 envelope glycoprotein gp120 and human CD4 (Kds = 8 and 15.8 nM, respectively). It also induces permeabilization of large unilamellar vesicles (LUVs) formed from 1-palmitoyl-2-oleoyl-sn-glycero-3-PG .

Reviews

Review for Defensin HNP-2 (human) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Defensin HNP-2 (human) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.